Supernus Pharmaceuticals SUPN Return on invested capital

Return on invested capital at other companies

AbbVieABBV

17.1%—

Rapport Therapeutics, Inc.RAPP

-52.1%+9.1pp

Acadia PharmaceuticalsACAD

10.7%-27.8pp

Axsome TherapeuticsAXSM

-3,891.6%—

Neurocrine BiosciencesNBIX

17.5%+5.1pp

XER

Xeris Biopharma Holdings, Inc.XERS

21.7%+17.8pp

FAQ

What is Supernus Pharmaceuticals's return on invested capital?

Supernus Pharmaceuticals (SUPN) reported return on invested capital of -6.4% in Q1 2026.

How has Supernus Pharmaceuticals's return on invested capital changed year-over-year?

Supernus Pharmaceuticals's return on invested capital decreased by 218.5% year-over-year, from 5.4% to -6.4%.

What is the long-term trend for Supernus Pharmaceuticals's return on invested capital?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's return on invested capital has grown at a -25.3% compound annual growth rate (CAGR), from 27.1% to -6.3%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.